Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-002631-42 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of the study was to determine the onset of Mavenclad® action by frequent magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in participants with highly active relapsing multiple sclerosis (MS).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mavenclad® | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mavenclad® | Drug | Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline Period (Period Screening to Baseline) in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Period 1 (Month 1-6) | CUA lesions were measured by using MRI scans. | Baseline period (the period screening to Baseline), Period 1 (Month 1-6) |
| Change From Baseline Period (Period Screening to Baseline) in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Period 2 (Month 2-6) | CUA lesions were measured by using MRI scans. | Baseline period (the period screening to Baseline), Period 2 (Month 2-6) |
| Change From Baseline Period (Period Screening to Baseline) in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Period 3 (Month 3-6) | CUA lesions were measured by using MRI scans. | Baseline period (the period screening to Baseline), Period 3 (Month 3-6) |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change From Baseline in Counts of Immune Cell Subsets - B Cells at Month 3, 6, 12, 15, 18 and 24 | B cell population counts are: CD19 B cells (TBNK panel), CD20 B cells (B cell panel), Memory B cells (B cell panel), Activated B cells (B cell panel), Total plasma cells (B cell panel), Short-lived plasma cells (B cell panel), Naïve B cells (B cell panel), Transitional B cells (B cell panel), and Regulatory B cells (B cell panel). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Responsible | Merck KGaA, Darmstadt, Germany | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Liverpool Hospital | Sydney | New South Wales | 2170 | Australia | ||
| John Hunter Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35701185 | Result | de Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Wiendl H, Keller B, Roy S; MAGNIFY-MS Study Group. Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS. Neurol Neuroimmunol Neuroinflamm. 2022 Jun 14;9(4):e1187. doi: 10.1212/NXI.0000000000001187. Print 2022 Jul. | |
| 41943490 |
| Label | URL |
|---|---|
| Trial Awareness and Transparency website | View source |
Not provided
Not provided
A total of 270 participants were enrolled in the study from different trial sites across14 countries (Austria, Germany, Hungary, Poland, Czechia, Italy, Spain, France, United Kingdom of Great Britain and Northern Ireland, Finland, Sweden, Israel, Australia and Canada).
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Experimental: Mavenclad® | Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 12, 2019 | May 4, 2021 |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Baseline, Month 3, 6, 12, 15, 18 and 24 |
| Percent Change From Baseline in Counts of Immune Cell Subsets - T Cells at Month 3, 6, 12, 15, 18 and 24 | T cell population counts are: Total CD4 T cells (TBNK panel), CD4 Th1 cells (T cell panel), CD4 Th17 T cells (T cell panel), CD4 Regulatory T cells (T cell panel), and Total CD8 T cells (TBNK panel). | Baseline, Month 3, 6, 12, 15, 18 and 24 |
| Percent Change From Baseline in Counts of Immune Cell Subsets - NK Cells at Month 3, 6, 12, 15, 18 and 24 | NK cell population counts are: CD16+ CD56+ NK Cells, CD16+ NK Cells, NK p46 cells, CD16lowCD56bright, and CD16brightCD56dim. | Baseline, Month 3, 6, 12, 15, 18 and 24. |
| Hunter Region Mail Centre |
| 2310-2305 |
| Australia |
| Perron Institute - Neurology | Nedlands | 6009 | Australia |
| The Alfred Hospital | Prahran | 3181 | Australia |
| Klagenfurt1 | Klagenfurt | 9020 | Austria |
| Paracelsus Medical University Salzburg | Salzburg | 5020 | Austria |
| MS Clinical Trials Group | Vancouver | British Columbia | V6T 1Z3 | Canada |
| UB - State University of New York | London | Ontario | N6A 5A5 | Canada |
| University of Alberta | Edmonton | T6G 2G3 | Canada |
| Montreal Neurological Hospital | Montreal | H3A 2B4 | Canada |
| Fakultni nemocnice Brno | Brno-Bohunice | Brno-Bohunice | 630 00 | Czechia |
| Nemocnice Pardubickeho kraje, a.s. Pardubicka nemocnice | Pardubice | Pardubice Region | 532 03 | Czechia |
| Fakultni nemocnice u sv. Anny v Brne | Brno | 65691 | Czechia |
| FN Hradec Kralove | Choceň | 56501 | Czechia |
| Fakultni nemocnice v Motole | Prague | 15006 | Czechia |
| Helsinki University Central Hospital | Helsinki | Finland |
| FinnMedi Oy vastaanotto - Finn-Medi 3 | Tampere | 33520 | Finland |
| Turku University Hospital | Turku | 20521 | Finland |
| CHU de Pontchaillou | Rennes | Ille Et Vilaine | 35033 | France |
| CHRU de Lille | Lille | 59037 | France |
| CHU Nice - Hôpital Pasteur | Nice | 06002 | France |
| CHU Montpellier-Nîmes - Hôpital Caremeau | Nîmes | 30004 | France |
| CHU Nîmes | Nîmes | 30029 | France |
| CHU de Poissy | Poissy | 78303 | France |
| Hôpital Civil | Strasbourg | 67091 | France |
| Universitätsklinikum Bonn | Bonn | 53105 | Germany |
| Universitätsklinikum Carl Gustav Carus | Dresden | 01307 | Germany |
| Neuro Centrum Science GmbH | Erbach im Odenwald | Germany |
| Universitätsklinikum Essen | Essen | Germany |
| Neurologische Praxis Eppendorf | Hamburg | Germany |
| Medizinische Hochschule Hannover | Hanover | 30625 | Germany |
| Universitätsklinikum Leipzig | Leipzig | 04103 | Germany |
| Universitätsklinikum Münster | Münster | 48149 | Germany |
| Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpo | Szeged | 6701 | Hungary |
| Barzilai Medical Center | Ashkelon | 78306 | Israel |
| Rambam MC | Haifa | 31096 | Israel |
| The Chaim Sheba Medical Center | Tel Litwinsky | 52621 | Israel |
| Policlinico Universitario SS Annunziata | Chieti | Italy |
| Seconda Univesità degli Studi di Napoli, AOU | Naples | 80131 | Italy |
| IRCSS Neuromed Istituto Neurologico Mediterraneo | Roma | 133 | Italy |
| Universita di SIENA | Siena | 53100 | Italy |
| Indywidualna Praktyka Lekarska Prof. Konrad Rejdak | Lublin | Lublin Voivodeship | 20-954 | Poland |
| Samodzielny Publiczny Szpital Kliniczny nr 7 SUM | Katowice | 40-662 | Poland |
| Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Stanislawa Szyszko SUM w Katowicach | Zabrze | 41-800 | Poland |
| Hospital de Cruces | Baracaldo Vizcaya | Vizcaya | 48903 | Spain |
| Hospital Universitario Puerta de Hierro Majadahonda | Madrid | 28035 | Spain |
| Hospital Clinico San Carlos | Madrid | 28046 | Spain |
| Hospital Vithas NISA Sevilla | Seville | 41009 | Spain |
| Hospital La Fe | Valencia | 46009 | Spain |
| Sahlgrenska Universitetssjukhus | Gothenburg | 416 85 | Sweden |
| Akademiskt Specialist Centrum - Centrum för Neurologi, plan 5 | Stockholm | 171 76 | Sweden |
| University Hospital of Wales | Cardiff | Wales | CF14 4XN | United Kingdom |
| Queen Elizabeth Hospital | Birmingham | B15 2TH | United Kingdom |
| Sheffield Teaching Hospitals Sheffield | Sheffield | SI0 2JF | United Kingdom |
| Derived |
| Schmierer K, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Sellebjerg F, Vermersch P, Jin H, Sponton L, Chudecka A, Bucello M, Gardner L, De Stefano N. A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study. Neurodegener Dis Manag. 2026 Apr 6:1-11. doi: 10.1080/17582024.2026.2646302. Online ahead of print. |
| 40756532 | Derived | Schmierer K, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Sellebjerg F, Vermersch P, Jin H, Sponton L, Chudecka A, Gardner L, De Stefano N. Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study. Ther Adv Neurol Disord. 2025 Jul 31;18:17562864251351760. doi: 10.1177/17562864251351760. eCollection 2025. |
| 39963134 | Derived | Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L, De Stefano N. Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Front Immunol. 2025 Feb 3;16:1512189. doi: 10.3389/fimmu.2025.1512189. eCollection 2025. |
| 36411081 | Derived | Wiendl H, Schmierer K, Hodgkinson S, Derfuss T, Chan A, Sellebjerg F, Achiron A, Montalban X, Prat A, De Stefano N, Barkhof F, Leocani L, Vermersch P, Chudecka A, Mwape C, Holmberg KH, Boschert U, Roy S; MAGNIFY-MS Study Group. Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 21;10(1):e200048. doi: 10.1212/NXI.0000000000200048. Print 2023 Jan. |
| 35672923 | Derived | Schmierer K, Wiendl H, Oreja-Guevara C, Centonze D, Chudecka A, Roy S, Boschert U. Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis. Mult Scler. 2022 Nov;28(13):2151-2153. doi: 10.1177/13524585221099413. Epub 2022 Jun 7. No abstract available. |
| Medical Information Location Map - Med Info Contacts | View source |
| Full Analysis Set (FAS) |
|
| COMPLETED |
|
| NOT COMPLETED |
|
Full analysis set (FAS) included all participants from the intent-to-treat (ITT [ITT population included all participants classified as eligible]) set who received at least one dose of the study treatment.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Experimental: Mavenclad® | Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline Period (Period Screening to Baseline) in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Period 1 (Month 1-6) | CUA lesions were measured by using MRI scans. | FAS included all participants from the ITT set who received at least one dose of the study treatment. Here, "Number of participants analyzed" signifies those participants who were evaluable for this outcome measure. | Posted | Mean | Standard Deviation | lesions | Baseline period (the period screening to Baseline), Period 1 (Month 1-6) |
|
|
| |||||||||||||||||||||||||
| Primary | Change From Baseline Period (Period Screening to Baseline) in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Period 2 (Month 2-6) | CUA lesions were measured by using MRI scans. | FAS included all participants from the ITT set who received at least one dose of the study treatment. Here, "Number of participants analyzed" signifies those participants who were evaluable for this outcome measure. | Posted | Mean | Standard Deviation | lesions | Baseline period (the period screening to Baseline), Period 2 (Month 2-6) |
|
| ||||||||||||||||||||||||||
| Primary | Change From Baseline Period (Period Screening to Baseline) in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Period 3 (Month 3-6) | CUA lesions were measured by using MRI scans. | FAS included all participants from the ITT set who received at least one dose of the study treatment. Here, "Number of participants analyzed" signifies those participants who were evaluable for this outcome measure. | Posted | Mean | Standard Deviation | lesions | Baseline period (the period screening to Baseline), Period 3 (Month 3-6) |
|
| ||||||||||||||||||||||||||
| Secondary | Percent Change From Baseline in Counts of Immune Cell Subsets - B Cells at Month 3, 6, 12, 15, 18 and 24 | B cell population counts are: CD19 B cells (TBNK panel), CD20 B cells (B cell panel), Memory B cells (B cell panel), Activated B cells (B cell panel), Total plasma cells (B cell panel), Short-lived plasma cells (B cell panel), Naïve B cells (B cell panel), Transitional B cells (B cell panel), and Regulatory B cells (B cell panel). | FAS included all participants from the ITT set who received at least one dose of the study treatment. Here, "Number of participants analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable at specified categories. | Posted | Median | Inter-Quartile Range | Percent change | Baseline, Month 3, 6, 12, 15, 18 and 24 |
|
| ||||||||||||||||||||||||||
| Secondary | Percent Change From Baseline in Counts of Immune Cell Subsets - T Cells at Month 3, 6, 12, 15, 18 and 24 | T cell population counts are: Total CD4 T cells (TBNK panel), CD4 Th1 cells (T cell panel), CD4 Th17 T cells (T cell panel), CD4 Regulatory T cells (T cell panel), and Total CD8 T cells (TBNK panel). | FAS included all participants from the ITT set who received at least one dose of the study treatment. Here, "Number of participants analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable at specified categories. | Posted | Median | Inter-Quartile Range | Percent change | Baseline, Month 3, 6, 12, 15, 18 and 24 |
|
| ||||||||||||||||||||||||||
| Secondary | Percent Change From Baseline in Counts of Immune Cell Subsets - NK Cells at Month 3, 6, 12, 15, 18 and 24 | NK cell population counts are: CD16+ CD56+ NK Cells, CD16+ NK Cells, NK p46 cells, CD16lowCD56bright, and CD16brightCD56dim. | FAS included all participants from the ITT set who received at least one dose of the study treatment. Here, "Number of participants analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable at specified categories. | Posted | Median | Inter-Quartile Range | Percent change | Baseline, Month 3, 6, 12, 15, 18 and 24. |
|
|
From baseline up to Month 45
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Experimental: Mavenclad® | Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. | 0 | 270 | 14 | 270 | 225 | 270 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Left ventricular dysfunction | Cardiac disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Diplopia | Eye disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Eye haemorrhage | Eye disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Eye pain | Eye disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Gastritis | Gastrointestinal disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Vestibular neuronitis | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Papillary thyroid cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Cerebrovascular accident | Nervous system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Carotid endarterectomy | Surgical and medical procedures | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Vertigo | Ear and labyrinth disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Hip fracture | Injury, poisoning and procedural complications | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Overdose | Injury, poisoning and procedural complications | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Ischaemic stroke | Nervous system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Skin lesion | Skin and subcutaneous tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Interspinous osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Lumbar spinal stenosis | Musculoskeletal and connective tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Fatigue | General disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Oral herpes | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Lymphopenia | Blood and lymphatic system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Muscle Spasm | Musculoskeletal and connective tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Neck Pain | Musculoskeletal and connective tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Pain in extrimity | Musculoskeletal and connective tissue disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Paraesthesia | Nervous system disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA version 24.0 | Non-systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA version 24.0 | Non-systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Communication Center | Merck KGaA, Darmstadt, Germany | +49-6151-72-5200 | service@emdgroup.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Sep 29, 2021 | Feb 20, 2023 | SAP_002.pdf |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D017338 | Cladribine |
| ID | Term |
|---|---|
| D015762 | 2-Chloroadenosine |
| D000241 | Adenosine |
| D011684 | Purine Nucleosides |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D003839 | Deoxyadenosines |
| D003853 | Deoxyribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D012263 | Ribonucleosides |
Not provided
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|
|
|